Port Erin Biopharma Investments (PEBI) Share Price, News & Analysis

Company Overview

Port Erin Biopharma Investments Limited is a principal investment firm specializing in investments in equity and equity related products. The firm invests in quoted and unquoted companies. It prefers to invest in the biopharma sector and will establish a portfolio of investments in biotechnology and biopharmaceutical companies. The firm may also invest in shares of collective investment schemes with exposure to the biopharma sector and in long-term equity anticipation securities the underlying securities of which will be based on biopharma sector securities and/or indices relating to the biopharma Sector. It may invest in biopharma sector debt, where investments shall not exceed 15 per cent of the net asset value of the company. Port Erin Biopharma Investments Limited was founded on May 3, 2011 and is based in Isle of Man, United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: 4.50 to 4.50
• 52-Week Range: N/A
• Volume: 8,294 shs
• Average Volume: 43,123 shs
• Market Capitalization: £1.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PEBI Stock Analysis - Frequently Asked Questions

How do I buy shares of Port Erin Biopharma Investments?

Shares of PEBI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:PEBI
• CUSIP: N/A
• CIK: N/A
• Web: www.porterinbiopharma.com
• Phone: +44-1624-620711
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 59.77
• Quick Ratio: 59.77

Sales & Book Value

• Annual Sales: £28,300.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 0.55
• Book Value: GBX 8.10 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 23,195,600
• Free Float: N/A
• Market Cap: £1.04 million
• Optionable: Not Optionable
• Beta: N/A